<--GAT-->

New SGLT2 Inhibitor Approved to Treat Type 2 Diabetes

by U.S. Medicine

February 5, 2014

WASHINGTON A new sodium-glucose co-transporter 2 (SGLT2) inhibitor has been approved to treat type 2 diabetes.

The Food and Drug Administration approved Farxiga (dapaglifozin) tablets to improve glycemic control, along with diet and exercise, in adults. Farxiga is marketed by Bristol-Myers Squibb Company, Princeton, NJ, and AstraZeneca Pharmaceuticals LP, Wilmington, DE.

Controlling blood sugar levels is very important in the overall treatment and care of diabetes, and Farxiga provides an additional treatment option for millions of Americans with type 2 diabetes,” said Curtis Rosebraugh, MD, MPH, director of the Office of Drug Evaluation II in the FDA’s Center for Drug Evaluation and Research.

SGLT2 inhibitors block the reabsorption of glucose by the kidney, increase glucose excretion and lower blood glucose levels.

Farxiga’s safety and effectiveness were evaluated in 16 clinical trials involving more than 9,400 patients with type 2 diabetes. The drug was shown to improve patients HbA1c measurements.

The studies involved Farxiga both as a monotherapy and in combination with other type 2 diabetes medications, including metformin, pioglitazone, glimepiride, sitagliptin and insulin.

The FDA noted that Farxiga should not be used to treat people with type 1 diabetes, diabetic ketoacidosis or moderate or severe renal impairment, end stage renal disease or who are on dialysis.

Because an increased number of bladder cancers were diagnosed among Farxiga users in clinical trials, the FDA also does not recommend Farxiga is not recommended for patients with active bladder cancer and suggests that patients with a history of bladder cancer talk to their physician before initiation of the therapy.

Farxiga can cause dehydration, leading to hypotension that can result in dizziness and/or fainting and a decline in renal function. The elderly, patients with impaired renal function and patients on diuretics to treat other conditions appeared to be more susceptible to this risk, the FDA said.

Six post-marketing studies are being required for Farxiga.

Genital mycotic (fungal) infections and urinary tract infections are among the drug’s side effects.


Related Articles

Suicide risk under-appreciated among advanced lung cancer patients

Much of the focus on suicide at the VA is on recently discharged servicemembers who suffer from conditions such as depression or post-traumatic stress disorder (PTSD).

New Agents Extend Options for Increased Survival in Metastatic Prostate Cancer

Accounting for nearly a third of all cancer diagnoses, prostate cancer is the most frequently diagnosed cancer in the VHA, where past research has suggested that the malignancy is caught earlier than in other healthcare systems.


U.S. Medicine Recommends


More From oncology

Oncology

Suicide risk under-appreciated among advanced lung cancer patients

Much of the focus on suicide at the VA is on recently discharged servicemembers who suffer from conditions such as depression or post-traumatic stress disorder (PTSD).

Oncology

New Agents Extend Options for Increased Survival in Metastatic Prostate Cancer

Accounting for nearly a third of all cancer diagnoses, prostate cancer is the most frequently diagnosed cancer in the VHA, where past research has suggested that the malignancy is caught earlier than in other healthcare systems.

Oncology

Personalized Medicine Brightens Outlook for Most Common Kidney Cancer

In the past five years, 10 new system therapies have been approved for renal cell carcinoma (RCC), the most common type of kidney cancer.

Oncology

Targeted Therapies Transform RCC Treatment Over Last Decade

In the last decade, the development of multiple molecular-targeted therapies has dramatically altered the treatment landscape for advanced renal cell carcinoma (RCC).

Oncology

Liver Cancer Continues to Rise, Even as VA Declares Victory Over HCV Infection

In March, then-VA Secretary David Shulkin, MD, announced at the annual Wharton Health Care Business Conference that the VA will have eliminated hepatitis C infections among all patients willing and able to be treated by next spring.

Facebook Comment

Subscribe to U.S. Medicine Print Magazine

U.S. Medicine is mailed free each month to physicians, pharmacists, nurse practitioners, physician assistants and administrators working for Veterans Affairs, Department of Defense and U.S. Public Health Service.

Subscribe Now

Receive Our Email Newsletter

Stay informed about federal medical news, clinical updates and reports on government topics for the federal healthcare professional.

Sign Up